In a patient with hyperkalemia (serum potassium 6.2 mmol/L) and chronic kidney disease stage 4, what is the appropriate dosing of Lokelma (sodium zirconium cyclosilicate)?

Lokelma Dosing for Hyperkalemia 6.2 mmol/L in Stage 4 CKD

For a patient with potassium 6.2 mmol/L and stage 4 CKD, start Lokelma (sodium zirconium cyclosilicate) 10 g three times daily for up to 48 hours, then transition to 10 g once daily for maintenance. 1

Initial Treatment Phase (Correction Phase)

The FDA-approved dosing for initial hyperkalemia treatment is 10 g administered three times daily for up to 48 hours 1. This regimen is specifically designed to rapidly lower potassium levels:

• Mix each 10 g dose in approximately 3 tablespoons of water
• Administer three times daily (morning, afternoon, evening)
• Continue until potassium normalizes (3.5-5.0 mmol/L) or for maximum 48 hours
• Separate from other oral medications by at least 2 hours 1

Clinical evidence supporting this approach: In phase 3 trials, 98% of patients achieved normokalemia within 48 hours using this three-times-daily regimen, with significant reductions observed within 1 hour of the first dose 2. For patients with severe hyperkalemia (≥6.0 mmol/L), mean reductions of 0.7 mmol/L occurred within the first 48 hours 3.

Maintenance Phase

After achieving normokalemia, transition to 10 g once daily 1. This is the standard maintenance dose for non-dialysis patients:

• Monitor serum potassium weekly initially, then adjust monitoring frequency based on stability
• Titrate dose in 5 g increments at intervals of 1 week or longer based on potassium levels
• Maintenance dose range: 5 g every other day to 15 g daily 1

Long-term efficacy data: In the 12-month open-label HARMONIZE extension study, 88% of patients maintained mean serum potassium ≤5.1 mmol/L during days 8-29 with once-daily dosing, and 93% achieved this target across the full 11-month period 2, 4. The mean daily dose required was 7.2 g (SD 2.6 g) 4.

Stage 4 CKD-Specific Considerations

Your patient's stage 4 CKD (eGFR 15-29 mL/min/1.73 m²) does not require dose adjustment from standard dosing 1. Post-hoc analysis of patients with eGFR <30 mL/min/1.73 m² showed:

• 82% achieved normokalemia within 24 hours during correction phase
• 100% achieved normokalemia within 72 hours
• 82% maintained normokalemia at day 365 during maintenance phase 5

The efficacy and safety profile in advanced CKD (stages 4-5) is comparable to earlier CKD stages 5.

Critical Monitoring Points

Monitor for edema: Each 5 g dose contains approximately 400 mg sodium 1. In stage 4 CKD with compromised fluid handling:

• Assess for peripheral edema at each visit
• Adjust diuretics as needed
• Consider dietary sodium restriction
• Edema was more common with 15 g daily dosing (14% incidence) versus lower doses 6

Hypokalemia risk: Check potassium 1 week after starting maintenance therapy and after any dose adjustment 1. In clinical trials, hypokalemia (<3.0 mmol/L) occurred in only 1% of patients, with 5% experiencing mild hypokalemia (3.0-3.4 mmol/L) 4.

Metabolic acidosis benefit: SZC may provide additional benefit in stage 4 CKD patients with concurrent metabolic acidosis, as it exchanges potassium for hydrogen ions, potentially raising serum bicarbonate 2, 7.

Medication Timing

Separate SZC from other oral medications by at least 2 hours before or after administration 1. This is particularly important for:

• Renin-angiotensin-aldosterone system inhibitors (ACE inhibitors, ARBs, MRAs)
• Thyroid medications
• Antibiotics

RAAS Inhibitor Management

Do not discontinue RAAS inhibitors during SZC initiation unless potassium exceeds 6.5 mmol/L 8, 2. The 2025 European guidelines emphasize that potassium binders like SZC enable continuation of disease-modifying therapies 8. In long-term studies, 87% of patients continued or increased RAAS inhibitor doses while on SZC 4.

Common Pitfalls to Avoid

1. Don't use SZC for emergency/life-threatening hyperkalemia - it has delayed onset compared to insulin/glucose or dialysis 1
2. Don't skip the three-times-daily correction phase - jumping directly to once-daily dosing will delay potassium normalization
3. Don't forget to adjust for constipation - avoid use in severe constipation or bowel obstruction 1
4. Don't under-dose in maintenance - if potassium rises above 5.0 mmol/L, uptitrate by 5 g increments rather than discontinuing 1